Contact Us

Company News

Home
Blog Standard
Company News
Page 3
Company News May 26, 2023 Oxford Vacmedix Comments: 0

Oxford Vacmedix feature in ‘Advancing Immunology’

Oxford Vacmedix to feature in ITN Business’ programme ‘Advancing Immunology’ – exploring the use of new technology to develop vaccines to treat cancer Oxford, UK – 26th May 2023 ITN Business present Oxford Vacmedix in a new series on ‘Advancing Immunology’. The programme explores how cancer therapeutic vaccines are being trialled and could reduce the need for invasive treatments such as chemotherapy and radiotherapy for some cancers in future. Watch Oxfo...
Read More
Company News May 12, 2023 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces major manufacturing milestone for OVM-200

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable two years post manufacture – a major milestone for OVM’s lead cancer vaccine development Oxford, UK – 12th May 2023 Press Release – Oxford Vacmedix announces major manufacturing milestone for OVM-200 Oxford Vacmedix (OVM), the UK-based biopharma company developing therapeutic cancer vaccines, announced today that OVM-200 which was manufactured on contract by Eurofins Amatsi to exacti...
Read More
Company News April 5, 2023 Oxford Vacmedix Comments: 0

Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford

New appointment In Professor Shisong Jiang’s research group in the Department of Oncology brings further expertise to research applications for Recombinant Overlapping Peptides (ROPs) Oxford, UK – 5th April 2023 Press Release – Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of therapeutic cancer vaccines, announced today the award of an MRC i-Case studentship to fund a new D.Ph...
Read More
Company News March 29, 2023 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed – the first clinical trial of a cancer vaccine using novel ROP technology. Oxford, UK – 29th March 2023 Press Release – Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of vaccines to treat cancer announced today the successful completion of a Pha...
Read More
Company News September 8, 2022 Oxford Vacmedix Comments: 0

OVM-200 Phase 1 Clinical Trial featured on TV

The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022. It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients. Professor Shisong Jiang, Chief Scientific Officer and Founder of OVM said: We see the potential benefits of a vaccination approach both in stimulating the body’s immune system to attack the...
Read More
Company News July 27, 2022 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test

New patent for a novel diagnostic test to detect anti-microbial resistance filed, after successful completion of development and initial testing Oxford, 27th July 2022 Press Release – Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test Oxford Vacmedix (OVM), the UK clinical stage biopharma company, focused on the development of a new generation of cancer vaccines, announced today that project work to develop a novel diagnostic test for anti-microbia...
Read More
Company News May 25, 2022 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays.  Project with Department of Oncology, University of Oxford and Reading Scientific Services (RSSL) to develop the methodology for T-cell potency assays of vaccines. Oxford, 25th May 2022 Press Release – Innovate UK funding for development of novel T-cell potency assays Oxford Vacmedix UK Limited (OVM) announced today the award of a Small Business Research Initiative contract from Innovate UK to fu...
Read More
Company News May 23, 2022 Oxford Vacmedix Comments: 0

Oxford Vacmedix founder Dr Shisong Jiang invited to Buckingham Place

Dr Shisong Jiang recieved an invitation to the annual Royal Garden Party to recognise many years’ service to charity. Oxford, 23rd May 2022 Press Release – Dr Shisong Jiang invited to Buckingham Palace On Wednesday 18 May, the Dr Shisong Jiang, the founder and CSO of Oxford Vacmedix, was invited to Buckingham Palace in London for the Royal Garden Party, an annual event that invites a broad range of people – all of whom have made a positive impact in their community – to be re...
Read More
Company News November 4, 2021 Oxford Vacmedix Comments: 0

First patient treated with novel Cancer Vaccine

A Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has started – the first clinical trial of a cancer vaccine using the novel technology. Press Release – Oxford group announces first patient treated with novel cancer vaccine Oxford, 4th November 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the start of a Phase 1 trial of OVM-200 with the first patient being treated at the prestigious Sarah...
Read More
Company News August 10, 2021 Oxford Vacmedix Comments: 0

MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200

Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform Oxford 10th August 2021; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 trial of OVM-200 has been received from the MHRA (Medicines and Healthcare products Regulatory Authority). Ethics approval for the trial has al...
Read More
en_GBEnglish
en_GBEnglish